Last reviewed · How we verify
Oxandrin
At a glance
| Generic name | Oxandrin |
|---|---|
| Also known as | Oxandrolone |
| Sponsor | Par Pharmaceutical, Inc. |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Catabolic Process
Common side effects
- Hepatic necrosis
- Hepatocellular neoplasms
- Peliosis hepatis
- Cholestatic jaundice
- Bleeding
- Hirsutism
- Male pattern baldness
- Acne
- Phallic enlargement
- Increased frequency or persistence of erections
- Impotence
- Chronic priapism
Key clinical trials
- Oxandrolone Multiligament Knee (PHASE4)
- Subdermal Implant-bioabsorbable Oxandrolone Pellet For Rehabilitation Following Anterior Cruciate Ligament (ACL) Surgical Reconstruction (PHASE2)
- Oxandrolone Rotator Cuff Trial (NA)
- Use of Oxandrolone to Promote Growth in Infants With HLHS (PHASE1, PHASE2)
- Placebo Versus Oxandrolone Supplementation in Trauma (PHASE3)
- Assessment of Mechanisms of Improved Wound Healing (PHASE2, PHASE3)
- Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer (PHASE3)
- Androgen Effect on Klinefelter Syndrome Motor Outcome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxandrin CI brief — competitive landscape report
- Oxandrin updates RSS · CI watch RSS
- Par Pharmaceutical, Inc. portfolio CI